Korea University Background
Need for research on active ingredients capable of treating or preventing obesity or chronic diseases:
For treating obesity, several drugs which suppressing appetite, have problems of severe side effects, including development of cardiovascular diseases.
Therefore, it is needed for research on active ingredients capable of treating or preventing obesity or chronic diseases using a safe food ingredient or an agent naturally produced in the body
A pharmaceutical composition for preventing or treating obesity that comprising azelaic acid as an active ingredient:
An azelaic acid () binds Olfr544, GPCR expressed in the cell membrane of the adipocytes, as a ligand, and activates Olfr544, which in turn activates the cAMP-PKA-HSL signalling pathway, thereby hydrolyzing triglycerides to decrease the concentration of triglycerides in adipocytes.
An azelaic acid has an effect of hydrolyzing triglycerides
When T3-L1 adipocytes were treated with 50 μM azelaic acid for 2 hours, the concentration of intracellular triglycerides was decreased by 61.5% compared to the control and the amount of glycerol was increased by 46.7% compared to the control ().
Azelaic acid hydrolyzes triglycerides to decrease the concentration of triglycerides in adipocytes.
The effect of decreasing a body weight and the anti-obesity effect
An azelaic acid is a natural product produced in the body and is contained in grains, such as barley, rye and the like.
An azelaic acid is an edible ingredient that acts on adipocytes in the body to increase triglyceride hydrolysis, thereby allowing the effect of decreasing a body weight and the anti-obesity effect.
The present technology is applied to prescription medicine such as anti-obesity drugs and functional foods such as diet foods.
The global market for anti-obesity drugs is expected to grow at CAGR 19.4% from $750 million in 2012 and reach $2.6 billion in 2019.
The market for anti-obesity drugs in Korea is estimated to be worth about 80 billion won and will continue to grow with the release of new products and the increasing demand for anti-obesity drugs.
– Built in laboratory environment.